Recent advances in the histopathology and molecular biology of prostate cancer

BJU International

Volumn 85, Issue 1, 2000, Pages 87-94

  Burton, J L ^a   Oakley, N ^b   Anderson, J B ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; PROTEIN P73;

ARTIFICIAL NEURAL NETWORK; CANCER GRADING; CYTOPATHOLOGY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR BIOLOGY; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR SUPPRESSOR GENE;

BIOPSY, NEEDLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA-BINDING PROTEINS; GENES, BCL-2; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NERVE NET; NUCLEAR PROTEINS; PHOSPHORIC MONOESTER HYDROLASES; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 0033970010     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00422.x     Document Type: Review

References (85)

1. 1 Borre M, Nerstrøm B, Overgaard J. The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer 1997; 80: 917-28
2. 2 Hirano D, Werahera PN, Crawford ED, Lucia MS, DeAntoni EP, Miller GJ. Morphological analysis and classification of latent prostate cancer using a 3-dimensional computer algorithm: analysis of tumor volume, grade, tumor doubling time and life expectancy. J Urol 1998; 159: 1265-9
3. 3 Dugan JA, Bostwick DG, Myres RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996; 275: 288-94
4. 4 Grönberg H, Damber L, Jonson K, Damber J-E. Prostate cancer mortality in northern Sweden, with special reference to tumor grade and patient age. Urology 1997; 49: 374-8
5. 5 Perrotti M, Rabbani F, Farkas A, Ward S, Cummings KB. Trends in poorly differentiated prostate cancer 1973-94: observations from the Surveillance, Epidemiology and End Results database. J Urol 1998; 160: 811-5
6. 6 Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in the USA. Lancet 1994; 343: 251-4
7. 7 deVere White RW, Deitch AD, Jackson AG. Radical differences in clinically localized prostate cancers of black and white men. J Urol 1998; 159: 1979-83
8. 8 Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273: 548-52
9. 9 Perrotti M, Rabbani F, Russo P, Solomon MC, Fair WR. Early prostate cancer detection and potential for surgical cure in men with poorly differentiated tumors. Urology 1998; 52: 106-10
10. 10 Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974-94. J Urol 1997; 158: 1427-30
11. 11 Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DT, Dibble RL. The fall in incidence of prostate cancer. On the down side of a prostate specific antigen induced peak in incidence - data from the Utah Cancer Registry. Cancer 1995; 77: 1342-8
12. 12 Bostwick DG, Qian J, Frankel K. The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. J Urol 1995; 154: 1791-4
13. 13 Orozco RE, O'Dowd G, Miller C, Veltri R. Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology 1998; 51: 186-95
14. 14 Mettlin CJ, Murphy GP. Why is the prostate cancer death rate declining in the United States? Cancer 1998; 82: 249-51
15. 15 Marshall WJ. Latest tests for prostatic neoplasia. J Clin Pathol 1998; 51: 347-50
16. 16 Davidson D, Bostwick DG, Qian J et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol 1995; 154: 1295-9
17. 17 Bauer JJ, Srivastava S, Connelly RR et al. Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. Urology 1998; 51: 970-6
18. 18 Giovannucci E, Rimm EB, Wolk A et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998; 58: 442-7
19. 19 Ingles SA, Coetzee GA, Ross RK et al. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 1998; 58: 1620-3
20. 20 Iczkowski KA, Bassler TJ, Schwob VS et al. Diagnosis of 'suspicious for malignancy' in prostate biopsies: predictive value for cancer. Urology 1998; 51: 749-58
21. 21 Wiley EL, Davidson P, McIntire DD, Sagalowsky AI. Risk of concurrent prostate cancer in cystoprostatectomy specimens is related to volume of high-grade prostatic intraepithelial neoplasia. Urology 1997; 49: 692-6
22. 22 Keetch DW, Humphrey PA, Stahl D, Smith DS, Catalona WJ. Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biospy of the prostate. J Urol 1995; 154: 347-51
23. 23 Harvei S, Skjørten FJ, Berner A, Tretli S. Is prostatic intraepithelial neoplasia in the transition/central zone a true precursor of cancer? A long-term retrospective study in Norway. Br J Cancer 1998; 78: 46-9
24. 24 Montironi R, Bostwick DG, Bonkhoff H et al. International consultation on prostatic intraepithelial neoplasia and pathologic staging of prostatic carcinoma. Origins of prostate cancer. Cancer 1996; 78: 362-5
25. 25 Cheng L, Shan A, Cheville JC, Qian J, Bostwick DG. Atypical adenomatous hyperplasia of the prostate: a premalignant lesion? Cancer Res 1998; 58: 389-91
26. 26 Engelstein D, Mukamel E, Cytron S, Konichezky M, Slutzki S, Servadio C. A comparison between digitally-guided fine needle aspiration and ultrasound-guided transperineal core needle biopsy of the prostate for the detection of prostate cancer. Br J Urol 1994; 74: 210-3
27. 27 Orozco RE, Kunnel BS, O'Dowd G, Stamey TA. positive prostate biopsy rate consistently increases with age at the same prostate-specific antigen level in patients with normal digital rectal examination. Urology 1998; 51: 531-3
28. 28 Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched needle biopsies. Am J Surg Pathol 1994; 18: 796-803
29. 29 Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995; 45: 2-12
30. 30 Epstein JI, Walsh PC, Sauvageot J, Carter HB. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol 1997; 158: 1886-90
31. 31 Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998; 159: 1247-50
32. 32 Cupp MR, Bostwick DG, Myres RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995; 153: 1543-8
33. 33 Wang X, Brannigan RE, Rademaker AW, McVary KT, Oyasu R. One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen. J Urol 1997; 158: 1431-5
34. 34 Ravery V, Szabo J, Toublanc M, Boccon-Gibod LA, Billebaud T, Hermieu JF. A single positive prostate biopsy in six does not predict a low-volume prostate tumour. Br J Urol 1996; 77: 724-8
35. 35 Vashi AR, Wojno KJ, Gillespie B, Oesterling JE. A model for the number of cores per prostate biopsy based on patient age and prostate gland volume. J Urol 1998; 159: 920-4
36. 36 Karakiewicz PI, Hartley JA, Bazinet M. Three-dimensional computer-assisted analysis of sector biopsy of the prostate. Urology 1998; 52: 208-12
37. 37 Eskew LA, Woodruff RD, Bare RL, McCullough DL. Prostate cancer diagnosed by the 5 region biopsy method is significant disease. J Urol 1998; 160: 794-6
38. 38 Chang JJ, Shinohara K, Hovey R, Montgomery C, Cresti JC Jr. Prospective evaluation of systematic sextant transition zone biopsies in large prostates for cancer detection. Urology 1998; 52: 89-93
39. 39 Lessells AM, Burnett RA, Howatson SR et al. Observer variability in the histopathological reporting of needle biopsy specimens of the prostate. Hum Pathol 1997; 28: 646-9
40. 40 Moul JW, Bauer JJ, Srivastava S, Colon E, Sesterhenn IA, McIeod DG. Perineal seeding of prostate cancer as the only evidence of clinical recurrence 14 years after needle biopsy and radical prostatectomy: molecular correlation. Urology 1998; 51: 158-60
41. 41 Lane RB Jr, Lane CG, Mangold KA, Johnson MH, Allsbrook WC Jr. Needle biopsies of the prostate. What constitutes adequate histologic sampling? Arch Pathol Lab Med 1998; 122: 833-5
42. 42 Reyes AO, Humphrey PA. Diagnostic effect of complete histological sampling of prostate needle biopsy specimens. Am J Clin Pathol 1998; 109: 416-22
43. 43 Cross SS. Grading and scoring in histopathology. Histopathology 1998; 33: 99-106
44. 44 Algabra F, Epstein JI, Aldape HC et al. International consultation on prostatic intraepithelial neoplasia and pathologic staging of prostatic carcinoma. Assessment of prostate carcinoma in core needle biopsy - definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer 1996; 78: 376-81
45. 45 Ruijter ET, van de Kaa CA, Schalken JA, Debruyne FM, Ruiter DJ. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 1996; 180: 295-9
46. 46 Carlson GD, Calvanese CB, Kahane H, Epstein JI. Accuracy of biopsy Gleason scores from a large uropathology laboratory: use of a diagnostic protocol to minimize observer variability. Urology 1999; 51: 525-9
47. 47 von Eschenbach AC, Brawer MK, Sant'Agnese PA et al. International consultation on prostatic intraepithelial neoplasia and pathologic staging of prostatic carcinoma. Exploration of new pathologic factors in terms of potential for prognostic significance and future applications. Cancer 1996; 78: 372-5
48. 48 Henneberry JM, Kahane H, Humphrey PA, Keetch DW, Epstein JI. The significance of intraluminal crystalloids in benign prostatic glands on needle biopsy. Am J Surg Pathol 1997; 21: 725-8
49. 49 Gaudin PB, Epstein JI. Adenosis of the prostate. Histologic features in needle biopsy specimens. Am J Surg Pathol 1995; 19: 737-47
50. 50 Anton RC, Chakraborty S, Wheeler TM. The significance of intraluminal prostatic crystalloids in benign needle biopsies. Am J Surg Pathol 1998; 22: 446-9
51. 51 Sant'Agnese PA. Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: a review of morphological aspects. Urology 1998; 51: 121-4
52. 52 Thorson P, Vollmer RT, Arcangeli C, Keetch DW, Humphrey PA. Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up. Mod Pathol 1998; 11: 543-51
53. 53 Kaleem Z, Swanson PE, Vollmer RT, Humphrey PA. Prostatic adenocarcinoma with atrophic features. A study of 202 consecutive completely embedded radical prostatectomy specimens. Am J Clin Pathol 1998; 109: 695-703
54. 54 Casella R, Bubendorf L, Sauter G, Moch H, Mihatsch MJ, Gasser TC. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. J Urol 1998; 160: 406-10
55. 55 Oppenheimer JR, Wills ML, Epstein JI. Partial atrophy in prostate needle cores. Another diagnostic pitfall for the surgical pathologist. Am J Surg Pathol 1998; 22: 440-5
56. 56 Samaratunga H, Singh M. Distribution pattern of basal cells detected by cytokeratin 34 beta E12 in primary prostatic duct adenocarcinoma. Am J Surg Pathol 1997; 21: 435-40
57. 57 Thomas SA, Brown IL, Hollins GW et al. Detection and distribution of heat shock proteins 27 and 90 in human benign and malignant prostatic tissue. Br J Urol 1996; 77: 367-72
58. 58 Ruijter ET, Miller GJ, Aalders TW et al. Rapid microwave-stimulated fixation of entire prostatectomy specimens. J Pathol 1997; 183: 369-75
59. 59 Naguib RNG, Robinson MC, Hamdy FC. Neural network analysis of combined conventional and experimental prognostic markers in prostate cancer: a pilot study. Br J Cancer 1998; 78: 246-50
60. 60 Montironi R, Santinelli A, Pomante R, Hamilton PW, Thompson D, Bartels PH. Inference network-based analyses of the histopathological effects of androgen deprivation on prostate cancer. J Pathol 1999; 187: 432-68
61. 61 Naitoh J, Witte O, Belldegrun A. The University of California, Los Angeles/Jennifer Jones Simon Foundation symposium on prostate cancer and epithelial cell biology: bringing together basic scientists and clinicians in the fight against advanced prostate cancer. Cancer Res 1998; 28: 2895-900
62. 62 Porter PL, Gown AM, Kramp SG, Coltrera MD. Widespread p53 overexpression in human malignant tumours: an immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol 1992; 140: 145-53
63. 63 Salem CE, Tomasic NA, Elmajian DA et al. p53 protein and gene alterations in pathological stage C prostate carcinoma. J Urol 1997; 158: 510-4
64. 64 Stapleton AMF, Zbell P, Kattan MW et al. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma after surgery. Cancer 1998; 82: 168-75
65. WAF1 and p53 proteins in prostatic cancer and their prognostic significance. Hum Pathol 1998; 29: 778-83
66. 66 Apakama I, Robinson MC, Walter NM et al. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 1996; 74: 1285-62
67. 67 Koivisto P, Rantala I. Amplification of the androgen receptor gene is associated with p53 mutation in hormone-refractory recurrent prostate cancer. J Pathol 1999; 187: 237-41
68. 68 Byrne RL, Wilson Horne CH, Robinson MC et al. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol 1997; 79: 190-5
69. 69 Moul JW, Bauer JJ, Sesterhenn IA, Stackhouse B, Srivastava S. Re: p53 protein and gene alterations in pathological stage C prostate carcinoma [letter]. J Urol 1997; 158: 1648
70. 70 Grossfield GD, Olumi AF, Connolly JA et al. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol 1998; 159: 1437-43
71. 71 Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic-alterations in hormone-refractory recurrent prostatic carcinomas. Am J Pathol 1998; 153: 141-8
72. 72 Yang M, Loda M, Sytkowski AJ. Identification of genes expressed differentially by LNCaP or PC-3 prostate cancer cell lines. Cancer Res 1998; 58: 3732-5
73. WAF1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential. Int J Cancer 1998; 77: 138-45
74. 1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res 1998; 58: 1920-9
75. 75 Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortaize pre-B cells. Nature 1988; 335: 440-2
76. 76 Wehrli BM, Krajeski S, Gascoyne RD, Gilks CB. Immunohiostochemical analysis of bcl-2, bax, mcl-1, and bcl-X expression in ovarian surface epithelial tumors. Int J Gynecol Pathol 1998; 17: 255-60
77. 77 Sinicrope FA, Ruan SB, Cleary KR, Stephens C, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995; 55: 237-41
78. 78 Tsuji M, Murakami Y, Kanayama H, Sano T, Kagawa S. Immunohistochemical analysis of Ki-67 antigen and bcl-2 protein expression in prostatic cancer: effect of neoadjuvant hormonal therapy. Br J Urol 1998; 81: 116-21
79. 79 Taniguchi J, Moriyama N, Kurimoto S, Kameyama S, Kawabe K. Histochemical detection of intranuclear DNA fragmentation and its relation to the expression of bcl-2 oncoprotein in human prostatic cancer. Br J Urol 1996; 77: 719-23
80. 80 Tang DG, Li L, Chopra DP, Porter AT. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins. Cancer Res 1998; 58: 3466-79
81. 81 Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson H. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997; 158: 131-7
82. 82 Teng DH-F, Hu R, Lin H et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997: 57: 5221-5
83. 83 Suzuki H, Freije D, Nusskern DR et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998; 58: 204-9
84. 84 Vlietstra RJ, van Alewijk DCJG, Hermans KGL, van Steenbrugge GJ, Trapman ]. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998; 58: 2720-3
85. 85 Takahashi H, Ichimiya S, Nimura Y et al. Mutation allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res 1998; 58: 2076-7